@article{6a549b074431446eb8a8c0a117754de3,
title = "Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger{\textquoteright}s Versus Healthy Controls: A Cross-Sectional Analysis",
abstract = "Biomarkers for autism spectrum disorder (ASD) are lacking but would facilitate drug development for the core deficits of the disorder. We evaluated markers proposed for characterization of differences in social communication and interaction in adults with ASD versus healthy controls (HC) for utility as biomarkers. Data pooled from an observational study and baseline data from a placebo-controlled study were analyzed. Between-group differences were observed in eye-tracking tasks for activity monitoring, biomotion, human activity preference, composite score (p = 0.0001–0.037) and pupillometry (various tasks, p = 0.017–0.05). Impaired olfaction was more common in the ASD sample versus HC (p = 0.018). Our preliminary results suggest the potential use for stratification and response sub-analyses outcome-prediction of specific eye-tracking tasks, pupillometry and olfaction tests in ASD trials",
keywords = "Biomarker, Eye movement, Olfactory, Social cognition",
author = "{Del Valle Rubido}, Marta and Eric Hollander and McCracken, {James T.} and Frederick Shic and Jana Noeldeke and Lauren Boak and Omar Khwaja and Shamil Sadikhov and Paulo Fontoura and Daniel Umbricht",
note = "Funding Information: EH has provided consultation to Roche and received research grants from Roche, Curemark, Coronado Biosciences, Forest, Simons Foundation, Foundation for Prader Willi Research, and the Orphan Products Division of the Food and Drug Administration, and has intellectual property relating to oxytocin and autism. FS has provided consultation to Roche and Janssen Pharmaceutical and has received research grants from Roche, NIH, and the Simons Foundation. JTM has served as a consultant for Roche and Dart Neuroscience, has received research grants from Roche, and has received study drug from Shire and AstraZeneca. FS has received research funding from Roche and Janssen Pharmaceuticals. MVR, DU, JN, LB, OK, SS and PF are full-time employees of F. Hoffmann-La Roche. Funding Information: The studies were funded by F. Hoffmann-La Roche. Medical writing and editing services were provided by Watermeadow Medical, an Ashfield Company, part of UDG Healthcare plc, funded by F. Hoffmann-La Roche. Acknowledgments Publisher Copyright: {\textcopyright} 2020, The Author(s).",
year = "2020",
month = dec,
doi = "10.1007/s10803-020-04493-5",
language = "English (US)",
volume = "50",
pages = "4412--4430",
journal = "Journal of Autism and Developmental Disorders",
issn = "0162-3257",
publisher = "Springer New York",
number = "12",
}